Proliferative Diabetic Retinopathy (PDR) Market Report 2026

The proliferative diabetic retinopathy (pdr) market size has grown rapidly in recent years. It will grow from $2.69 billion in 2025 to $2.96 billion in 2026 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to increasing prevalence of diabetes mellitus, wider use of retinal laser therapies, expansion of ophthalmology clinics, improved access to eye care services, growth in diabetic screening programs.

The proliferative diabetic retinopathy (pdr) market size is expected to see rapid growth in the next few years. It will grow to $4.49 billion in 2030 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to increasing demand for long-acting injectable therapies, rising adoption of AI-based retinal diagnostics, expansion of outpatient ophthalmic procedures, growing focus on vision preservation strategies, increasing investment in diabetic eye disease management. Major trends in the forecast period include increasing adoption of anti-vegf therapies, rising use of advanced retinal imaging technologies, growing focus on early screening and diagnosis, expansion of minimally invasive surgical interventions, enhanced integration of multidisciplinary diabetes care.

The increasing prevalence of diabetes is expected to drive the growth of the proliferative diabetic retinopathy (PDR) market in the coming years. Diabetes is a long-term medical condition characterized by elevated levels of glucose in the blood. It is the primary cause of proliferative diabetic retinopathy, a condition that can be managed through various treatment approaches aimed at preventing further retinal damage and preserving vision. For instance, in June 2024, according to the National Health Service, a UK-based government department, the number of individuals under the age of 40 living with diabetes increased from 173,166 in 2022 to 216,440 in 2023. This sharp rise highlights a concerning trend within this younger age group and reflects the rapid growth of diabetes prevalence among younger populations. Therefore, the rising prevalence of diabetes is fueling the growth of the proliferative diabetic retinopathy market.

Major companies operating in the proliferative diabetic retinopathy market are concentrating on the development of innovative technologies, such as AI-based autonomous retinal screening systems and handheld fundus cameras, to improve early detection and patient outcomes. AI-based autonomous screening systems are designed to independently analyze retinal images, enabling fast and accurate identification of diabetic retinopathy, while handheld fundus cameras offer portable and convenient retinal imaging solutions. For instance, in April 2024, Optomed Plc, a Finland-based medical technology company, received clearance from the U.S. Food and Drug Administration for its Optomed Aurora with AEYE, a handheld AI-powered fundus camera capable of autonomously detecting referable diabetic retinopathy. This approval expands access to efficient PDR screening beyond traditional clinical environments.

In July 2024, Merck and Co. Inc., a US-based healthcare company engaged in the development and commercialization of medicines, vaccines, and animal health products, acquired Eyebiotech Limited for $3 billion. Through this acquisition, Merck and Co. Inc. seeks to strengthen its ophthalmology pipeline by advancing innovative treatments for vision-threatening retinal disorders and addressing significant unmet medical needs in this field. Eyebiotech Limited is a UK-based biotechnology company focused on developing therapies for proliferative diabetic retinopathy aimed at reducing abnormal retinal blood vessel growth.

Major companies operating in the proliferative diabetic retinopathy (pdr) market are Johnson And Johnson Limited, F Hoffmann La Roche Ltd, AbbVie Inc, Bayer AG, Novartis AG, Merck KGaA, Kubota Vision Inc, Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc, Mylan NV, Santen Pharmaceutical Co Ltd, Lupin Limited, Genentech Inc, Alcon Inc, Carl Zeiss Meditec AG, Topcon Corporation, Nidek Co Ltd, Bausch And Lomb Corporation, Heidelberg Engineering GmbH, Iridex Corporation, Lumenis Ltd, Optos plc, Zeiss Meditec India Pvt Ltd, Alimera Sciences Inc.

North America was the largest region in the proliferative diabetic retinopathy market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the proliferative diabetic retinopathy (pdr) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the proliferative diabetic retinopathy (pdr) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the proliferative diabetic retinopathy market by increasing costs of imported ophthalmic drugs, retinal imaging devices, laser systems, and surgical instruments. Hospitals and eye clinics in North America and Europe are most affected due to reliance on imported anti-VEGF therapies and advanced diagnostic equipment, while Asia-Pacific faces cost pressure on expanding eye care infrastructure. These tariffs are raising treatment costs and slowing technology adoption. However, they are also supporting local production of ophthalmic devices, regional drug manufacturing, and investment in cost-effective retinal care solutions.

The proliferative diabetic retinopathy (pdr) market research report is one of a series of new reports that provides proliferative diabetic retinopathy (pdr) market statistics, including proliferative diabetic retinopathy (pdr) industry global market size, regional shares, competitors with a proliferative diabetic retinopathy (pdr) market share, detailed proliferative diabetic retinopathy (pdr) market segments, market trends and opportunities, and any further data you may need to thrive in the proliferative diabetic retinopathy (pdr) industry. This proliferative diabetic retinopathy (pdr) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Proliferative diabetic retinopathy (PDR) is an advanced form of diabetic eye disease marked by the development of abnormal blood vessels in the retina as a result of long-term elevated blood sugar levels. These abnormal vessels can cause retinal bleeding, scarring, and vision loss if not treated, making routine eye examinations essential for early detection and effective management.

The primary treatment options for proliferative diabetic retinopathy include anti-VEGF (vascular endothelial growth factor) therapy, intraocular steroids, laser surgery, and vitrectomy. Intraocular steroids are drugs delivered directly into the eye to control inflammation and manage conditions such as diabetic macular edema or uveitis, helping to reduce swelling and improve visual outcomes. The different modes of administration include injectables, oral formulations, and others, and these treatments are utilized across various settings such as hospitals, clinics, and other healthcare facilities.

The proliferative diabetic retinopathy (PDR) market consists of sales of laser therapy, systemic therapies and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The proliferative diabetic retinopathy (PDR) market also includes sales of corticosteroids, ranibizumab, bevacizumab and fluocinolone acetonide drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.